Table 3.
Parameters changed in the sensitivity analysis and changes on net cash benefit.
| Base case (net
benefit) |
−€482 |
Min |
Max |
||||
|---|---|---|---|---|---|---|---|
| Parameter | Base value | Value (–50%) | Net benefit | Actual change | Value (+50%) | Net benefit | Actual change |
| Probabilities | |||||||
| (P) severe TEAEs (Picato® (Lebwohl et al.6)) | 0.022 | –50% | –€480 | €2 | +50% | –€485 | –€2 |
| (P) severe TEAEs (Solaraze®) | 0.050 | –50% | –€487 | –€5 | +50% | –€478 | €5 |
| (P) complete lesion clearance (Picato® (Lebwohl et al.6)) | 0.422 | –50% | –€6.771 | –€6.288 | +50% | €5.806 | €6.288 |
| (P) complete lesion clearance (Solaraze®) | 0.580 | –50% | €8.161 | €8.643 | +50% | –€9.126 | –€8.643 |
| (P) recurrence (Picato® (Lebwohl et al.6)) | 0.128 | –50% | –€477 | €6 | +50% | –€488 | –€6 |
| (P) recurrence (Solaraze®) | 0.210 | –50% | –€494 | –€12 | +50% | –€471 | €12 |
| Costs | |||||||
| Net price (Picato® (Lebwohl et al.6)) | €65 | –50% | –€450 | €32 | +50% | –€515 | –€32 |
| Cost of specialist visit | €21 | 15.00 | –€482 | –€ | 85.00 | –€482 | –€ |
| Cost of recurrence (dermatology consultation) | €21 | 15.00 | –€482 | €1 | 85.00 | –€488 | –€6 |
| Utilities | |||||||
| Utility for complete lesion clearance (no recurrence) | 0.997 | –50% | €866 | €1.349 | N/A | N/A | N/A |
| Utility for complete lesion clearance (recurrence) | 0.993 | –50% | €527 | €1.010 | N/A | N/A | N/A |
| Utility for incomplete lesion clearance (recurrence) | 0.901 | –50% | –€2.416 | –€1.934 | N/A | N/A | N/A |
| Disutility for TEAEs | 0.085 | –50% | –€485 | –€3 | +50% | –€480 | €3 |
| Duration of TEAEs (weeks) | 4 | –50% | –€485 | –€3 | +50% | –€480 | €3 |
| Base case (net
benefit) |
–€680 |
Min |
Max |
||||
| Parameter | Base value | Value (–50%) | Net benefit | Actual change | Value (+50%) | Net benefit | Actual change |
| Probabilities | |||||||
| (P) severe TEAEs (Zyclara®, 3.75%) | 0.035 | –50% | –€677 | €3 | +50% | –€683 | –€3 |
| (P) severe TEAEs (Solaraze®) | 0.050 | –50% | –€685 | –€5 | +50% | –€675 | €5 |
| (P) complete lesion clearance (Zyclara®, 3.75%) | 0.356 | –50% | –€5.982 | –€5.302 | +50% | €4.622 | €5.302 |
| (P) complete lesion clearance (Solaraze®) | 0.580 | –50% | €7.963 | €8.643 | +50% | –€9.323 | –€8.643 |
| (P) recurrence (Zyclara®, 3.75%) | 0.210 | –50% | –€672 | €8 | +50% | –€688 | –€8 |
| (P) recurrence (Solaraze®) | 0.210 | –50% | –€692 | –€12 | +50% | –€668 | €12 |
| Costs | |||||||
| Net price (Zyclara®, 3.75%) | €61 | –50% | –€649 | €31 | +50% | –€711 | –€31 |
| Cost of specialist visit | €21 | 15.00 | –€680 | –€0 | 85.00 | –€680 | –€0 |
| Cost of recurrence (dermatology consultation) | €21 | 15.00 | –€679 | €1 | 85.00 | –€691 | –€11 |
| Utilities | |||||||
| Utility for complete lesion clearance (no recurrence) | 0.997 | –50% | €1.965 | €2.645 | N/A | N/A | N/A |
| Utility for complete lesion clearance (recurrence) | 0.993 | –50% | €21 | €701 | N/A | N/A | N/A |
| Utility for incomplete lesion clearance (recurrence) | 0.901 | –50% | –€3.422 | –€2.742 | N/A | N/A | N/A |
| Disutility for TEAEs | 0.085 | –50% | –€682 | –€1 | +50% | –€679 | €1 |
| Duration of TEAEs (weeks) | 4 | –50% | –€682 | –€1 | +50% | –€679 | €1 |
TEAEs: treatment-emergent adverse events.